- Home
- CLDI vs APRE Comparison
CLDI vs APRE Comparison
Compare CLDI & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- APRE
- Stock Information
- Founded
- CLDI 2014
- APRE 2006
- Country
- CLDI United States
- APRE United States
- Employees
- CLDI N/A
- APRE N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLDI Health Care
- APRE Health Care
- Exchange
- CLDI Nasdaq
- APRE Nasdaq
- Market Cap
- CLDI 8.7M
- APRE 8.3M
- IPO Year
- CLDI N/A
- APRE 2019
- Fundamental
- Price
- CLDI $1.58
- APRE $1.57
- Analyst Decision
- CLDI
- APRE Strong Buy
- Analyst Count
- CLDI 0
- APRE 1
- Target Price
- CLDI N/A
- APRE $20.00
- AVG Volume (30 Days)
- CLDI 161.6K
- APRE 65.7K
- Earning Date
- CLDI 11-11-2025
- APRE 11-06-2025
- Dividend Yield
- CLDI N/A
- APRE N/A
- EPS Growth
- CLDI N/A
- APRE N/A
- EPS
- CLDI N/A
- APRE N/A
- Revenue
- CLDI N/A
- APRE $841,012.00
- Revenue This Year
- CLDI N/A
- APRE N/A
- Revenue Next Year
- CLDI N/A
- APRE N/A
- P/E Ratio
- CLDI N/A
- APRE N/A
- Revenue Growth
- CLDI N/A
- APRE N/A
- 52 Week Low
- CLDI $1.41
- APRE $1.37
- 52 Week High
- CLDI $46.68
- APRE $5.01
- Technical
- Relative Strength Index (RSI)
- CLDI 44.14
- APRE 56.76
- Support Level
- CLDI $1.51
- APRE $1.40
- Resistance Level
- CLDI $1.74
- APRE $1.53
- Average True Range (ATR)
- CLDI 0.10
- APRE 0.08
- MACD
- CLDI 0.04
- APRE 0.02
- Stochastic Oscillator
- CLDI 30.43
- APRE 68.63
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.